


“It is concluded that maintenance treatment of ulcerative colitis with sulphasalazine (salazopyrin) should be continued indefinitely unless contraindicated by side effects”¹.

The results of the above controlled trial carried out at the Nuffield Department of Clinical Medicine, Radcliffe Infirmary, Oxford, are all the more welcome as earlier trials of cortisone² and prednisone³ at standard dosages have shown them to be totally ineffective in reducing the number of recurrences of ulcerative colitis.

“Fortunately, Sulphasalazine tablets, 0.5 grams, 4 times a day will prevent relapses in the majority of patients with colitis, and only a few patients cannot tolerate this relatively small dose, which can be continued indefinitely, since we do not know when, if ever, it can be safely stopped”⁴.



“The patients who received dummy tablets had more than four times the relapse rate of those receiving sulphasalazine”¹ (Salazopyrin).

Salazopyrin (sulphasalazine) is available as the plain 0.5 g. tablet, 0.5 g. EN-tab and as an 0.5 g. suppository. Literature and detailed information on Salazopyrin are available on request.

References

1. Gut (1973) 14 923-926
2. Brit. med. J. (1959) 1 387-394
3. Lancet (1965) i 188-189
4. General Practitioner (1972) April 7 p 11.

Salazopyrin— to be continued indefinitely

Further information on request from:—

Salazopyrin is a registered trade mark.

Pharmacia (Great Britain) Ltd.,
Paramount House,
75 Uxbridge Road,
London W5 5SS.
Telephone: 01-579 0102/7



Pharmacia